



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 10, 2005.

STW  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1614  
Patent Application  
Docket No. USF-T195XC1  
Serial No. 10/764,728

  
Jenna M. Morrison, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

  
Examiner : (Not yet assigned)  
Art Unit : 1614  
Applicants : Q. Ping Dou, Tak-Hang Chan, David M. Smith  
Serial No. : 10/764,728  
Filed : January 26, 2004  
For : Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited references are enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,

  
Jenna M. Morrison  
Patent Attorney  
Registration No. 55,468  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein.

J:\USF\T195XC1\PTO\SIDS1.pto.doc\DNB/mv



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/764,728
Filing Date	January 26, 2004
First Named Inventor	Q. Ping Dou
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	USF-T195XC1

Sheet 1 of 1

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	KAZI, A. <i>et al.</i> "Inhibition of Bcl-X <sub>L</sub> phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis" <i>Mol. Pharmacology</i> , 2002, 62(4):765-771.	
	R2	KAZI, A. <i>et al.</i> "Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention" <i>In Vivo</i> , 2002, 16(6):397-403.	
	R3	SMITH, D.M. <i>et al.</i> "Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design" <i>Proteins</i> , 2004, 54:58-70.	
	R4	SMITH, D.M. <i>et al.</i> "Synthetic analogs of green tea polyphenols as proteasome inhibitors" <i>Mol. Med.</i> , 2002, 8(7):382-392.	
	R5	SMITH, D.M. and DOU, Q.P. "Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis" <i>Int. J. Mol. Med.</i> , 2001, 7(6):645-652.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.